Intramuscular Olanzapine/Parenteral Benzodiazepines
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
How this interaction occurs is not known.
What might happen:
If you take these medicines together, you may experience increased sedation/sleepiness, loss of consciousness, slow breathing, and/or a slow/irregular heartbeat.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. If you experience a loss of consciousness, slow breathing, and/or a slow/irregular heartbeat, contact your doctor right away.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Zyprexa (olanzapine) intramuscular Canadian prescribing information. Lilly April 3, 2008.
2.Zyprexa (olanzapine) powder for solution for injection UK summary of product characteristics. Eli Lilly and Company Limited July 28, 2008.
3.Zyprexa (olanzapine) US prescribing information. Eli Lilly and Company August, 2012.
4.Sorsaburu S, Hornbuckle K, Blake DS. The first 21 months of safety experience with post-marketing use of olanzapine's intramuscular formulation. (Abstract NR432). Presented at the 159th Annual Meeting American Psychiatry Association. Toronto, Canada, May, 2006..
